The article discusses the microstructure and material composition of bone and chronic kidney disease (CKD). Topics discussed include the sensitivity lacking in the bone densitometry for the identification of individuals with sustaining fractures, the capability of the zoledronate, risedronate, and denosumab in the reduction of the classes of fracture.